Spots Global Cancer Trial Database for t cell therapy
Every month we try and update this database with for t cell therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) | NCT04752358 | Esophageal Canc... Esophagogastric... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | NCT02592577 | Non-Small Cell ... Carcinoma | Autologous Gene... | 18 Years - | Adaptimmune | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients | NCT00058656 | Chronic Lymphoc... | Infusion of Act... | 18 Years - | Xcyte Therapies | |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | NCT04044859 | Endometrial Can... Esophageal Canc... Esophagogastric... Gastric (Stomac... Head and Neck C... Melanoma Ovarian Cancer Non-small Cell ... Urothelial Canc... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation | NCT04180059 | Haematologic Di... | CTL 19 | 18 Years - 75 Years | Nantes University Hospital | |
| Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | NCT03197025 | Human Papilloma... HPV-16 High Grade Squa... | Aldesleukin E6 T Cell Recep... | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | NCT05908643 | Colorectal Canc... | pTTL | 18 Years - | Neogap Therapeutics AB | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors | NCT03391791 | Solid and Hemat... | Genetically eng... | 18 Years - | Adaptimmune | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | NCT00048464 | Multiple Myelom... | Infusion of Act... | 18 Years - 70 Years | Xcyte Therapies | |
| Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | NCT03197025 | Human Papilloma... HPV-16 High Grade Squa... | Aldesleukin E6 T Cell Recep... | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer | NCT02577588 | Colorectal Carc... | re-activated T ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers | NCT05035407 | Kita-kyushu Lun... | IL-2 (Aldesleuk... Cyclophosphamid... KK-LC-1 TCR Fludarabine | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors | NCT03391791 | Solid and Hemat... | Genetically eng... | 18 Years - | Adaptimmune | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | NCT05908643 | Colorectal Canc... | pTTL | 18 Years - | Neogap Therapeutics AB | |
| A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | NCT05908643 | Colorectal Canc... | pTTL | 18 Years - | Neogap Therapeutics AB | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | NCT04688853 | Multiple Myelom... Multiple Myelom... Multiple Myelom... | TEG002 | 18 Years - | Gadeta B.V. | |
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) | NCT04752358 | Esophageal Canc... Esophagogastric... | Autologous gene... | 18 Years - 75 Years | Adaptimmune |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
